In 2013 the US FDA provided an accelerated approval for the use of pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory or early-stage breast cancer (either >2 cm in diameter or node-positive) as part of complete treatment regimen for early breast cancer [44]. The gene discussed is ERBB2; the disease is breast carcinoma.